121 related articles for article (PubMed ID: 38551790)
1. DUSP1 Promotes Osimertinib Drug-Tolerant Persistence by Inhibiting MAPK/ERK Signaling in Non-small Cell Lung Cancer.
He W; Liu P; Lei Q; Xu J; Liu L
Mol Biotechnol; 2024 Mar; ():. PubMed ID: 38551790
[TBL] [Abstract][Full Text] [Related]
2. [Impact of Folic Acid on the Resistance of Non-small Cell Lung Cancer Cells
to Osimertinib by Regulating Methylation of DUSP1].
He W; Liu L
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):881-888. PubMed ID: 38163975
[TBL] [Abstract][Full Text] [Related]
3. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling.
Wang W; Xia X; Chen K; Chen M; Meng Y; Lv D; Yang H
Front Oncol; 2021; 11():665045. PubMed ID: 34168988
[TBL] [Abstract][Full Text] [Related]
4. YAP1 synergize with YY1 transcriptional co-repress DUSP1 to induce osimertinib resistant by activating the EGFR/MAPK pathway and abrogating autophagy in non-small cell lung cancer.
Ning Y; Zheng H; Yang Y; Zang H; Wang W; Zhan Y; Wang H; Luo J; Wen Q; Peng J; Xiang J; Fan S
Int J Biol Sci; 2023; 19(8):2458-2474. PubMed ID: 37215986
[TBL] [Abstract][Full Text] [Related]
5. The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Huang WC; Yadav VK; Cheng WH; Wang CH; Hsieh MS; Huang TY; Lin SF; Yeh CT; Kuo KT
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885115
[TBL] [Abstract][Full Text] [Related]
6. Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.
Takahashi H; Sakakibara-Konishi J; Furuta M; Shoji T; Tsuji K; Morinaga D; Kikuchi E; Kikuchi J; Noguchi T; Hatanaka KC; Hatanaka Y; Shinagawa N; Konno S
Cancer Sci; 2023 Apr; 114(4):1635-1650. PubMed ID: 36411521
[TBL] [Abstract][Full Text] [Related]
7. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
8. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
9. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
10. Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.
Chen V; Iwama E; Kim IK; Giaccone G
Lung Cancer; 2020 Jul; 145():48-57. PubMed ID: 32408132
[TBL] [Abstract][Full Text] [Related]
11. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
12.
He Z; Gong F; Liao J; Wang Q; Su Y; Chen C; Lin J; Lin RJ
Transl Cancer Res; 2020 Apr; 9(4):2542-2555. PubMed ID: 35117614
[TBL] [Abstract][Full Text] [Related]
13.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
14. PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression.
Jiang Y; Zhuo X; Wu Y; Fu X; Mao C
Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119144. PubMed ID: 34599981
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells.
Wang RH; Chang CJ; Chen CH; Liu KK; Chao JI
Anticancer Agents Med Chem; 2023; 23(11):1309-1319. PubMed ID: 36815658
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
[TBL] [Abstract][Full Text] [Related]
17. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
[TBL] [Abstract][Full Text] [Related]
18. Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells.
Hisakane K; Seike M; Sugano T; Yoshikawa A; Matsuda K; Takano N; Takahashi S; Noro R; Gemma A
Thorac Cancer; 2021 Jun; 12(11):1690-1698. PubMed ID: 33939301
[TBL] [Abstract][Full Text] [Related]
19. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
